Werfen and IL buy Accriva
Feb. 6, 2017—Accriva Diagnostics, a Warburg Pincus portfolio company, announced a definitive agreement with Werfen, headquartered in Barcelona, Spain, and its subsidiary Instrumentation Laboratory, headquartered in Bedford, Mass., in which Werfen and IL have acquired all shares of Accriva. The transaction closed on Jan. 19, 2017.
The Accriva portfolio, including point-of-care diagnostic products for coagulation and anti-platelet therapy response, will allow IL to establish a market-leading position in hospital-based POC hemostasis testing, expand its position in POC critical care testing, and complement its leadership in the hemostasis laboratory segment, according to a company statement.
Accriva Diagnostics, which employs approximately 460 employees, will become part of IL, a Werfen company, and will continue operating out of its existing San Diego facility.
“The acquisition of Accriva strengthens our leadership in hemostasis, critical care, and patient blood management testing,” Ramon Benet, CEO at IL, said. “We see great synergy between our organizations and look forward to further impacting positive clinical outcomes and reducing health care costs in point-of-care testing with the breadth of this comprehensive portfolio.”